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Cardiovascular disease is the single largest cause of death in the western world and its
incidence is on the rise globally. Atherosclerosis, characterized by the development of
atheromatus plaque, can trigger luminal narrowing and upon rupture result in myocardial
infarction or ischemic stroke. Epigenetic phenomena are a focus of considerable research
interest due to the role they play in gene regulation. Epigenetic mechanisms such as
DNA methylation and histone acetylation have been identiﬁed as potential drug targets
in the treatment of cardiovascular disease. miRNAs are known to play a role in gene
silencing, which has been widely investigated in cancer. In comparison, the role they
play in cardiovascular disease and plaque rupture is not well understood. Nutritional
epigenetic modiﬁers from dietary components, for instance sulforaphane found in broccoli,
have been shown to suppress the pro-inﬂammatory response through transcription factor
activation. This review will discuss current and potential epigenetic therapeutics for
the treatment of cardiovascular disease, focusing on the use of miRNAs and dietary
supplements such as sulforaphane and protocatechuic aldehyde.
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ATHEROSCLEROSIS
Cardiovascular disease (CVD) is the main cause of death in the
western world and its incidence globally is on the rise. It is a
multifactorial disease whereby known genetic and environmen-
tal effects account for only part of the variability in disease risk
(Ordovas and Smith, 2010). Atherosclerosis is the primary cause
of CVD and it is characterized by the development of an athero-
matus plaque, which triggers luminal narrowing. Plaque rupture
can result in myocardial infarction or ischemic stroke.
Atherosclerosis can be deﬁned as a disturbed balance of lipid
accumulation, giving rise to chronic inﬂammation of the arterial
wall (Weber and Noels, 2011). Inﬂammation leads to the recruit-
ment of a variety of immune cells, such as monocytes and T-cells,
which lead to further inﬂammatory signaling and recruitment.
This results in the development of a slow progressing lesion and
luminal narrowing due to the accumulation of sub-endothelial low
density lipoprotein (LDL) and immune cells (Moore and Tabas,
2011).
The initiating phase of plaque development occurs as a result of
injury to the endothelium, sources of which include hypercholes-
terolemia, hypertension, cigarette smoke, diabetes, and obesity;
these are often chronic and thereforeprogress uninterrupted (Ross,
1993). This is followed by the formation of a fatty streak due to
the accumulation of foam cells, which are modiﬁed macrophages
(Hansson and Libby, 2006). A mature plaque develops over time
and contains a wider variety of cell types. These have a more
complex structure consisting of a necrotic, lipid rich core, and a
ﬁbrous cap, the disruption of which leads to the clinical pheno-
types mentioned previously (Jonasson et al., 1986). Immune cells
are located at the edge of the cap, and upon activation express
inﬂammatory cytokines such as IFN-γ and TNFα which induce
vascular cell adhesion molecule-1 (VCAM-1) expression (Cybul-
sky and Gimbrone, 1991). Elevated levels of circulating cholesterol
support CVD and atherosclerosis, which leads to the expression of
adhesion molecules and chemokines by endothelial cells, further
driving immune inﬁltration (Hansson and Hermansson, 2011).
Atherosclerotic plaques often develop at regions where the arteries
branch, where blood ﬂow is non-linear and exerts low shear stress
(LSS), which upregulates inﬂammatory signaling and modulates
miRNAs to promote inﬂammation and monocyte recruitment
(Poller et al., 2013; Raitoharju et al., 2013; Webster et al., 2013).
EPIGENETIC MODIFICATIONS
Epigenetic mechanisms such as DNA methylation, post transla-
tional modiﬁcation (PTM) of histone proteins and RNA mech-
anisms have been widely investigated in multiple diseases. DNA
methylation occurs primarily on CpG dinucleotides and is asso-
ciated with transcriptional repression through the inhibition of
transcription factor binding (De Nigris et al., 2002; Dupont et al.,
2009; Burdge and Lillycrop, 2010; Yan et al., 2010). Key PTMs to
histone proteins include acetylation, methylation, and phospho-
rylation. These histone modiﬁcations are carried out by various
families of enzymes which determine promoter accessibility (De
Ruijter et al., 2003; Arrowsmith et al., 2012). RNA mechanisms
such as non-coding RNAs (ncRNAs) have the ability to alter gene
expression in a variety of ways and play regulatory roles during
development, the response to stress and environmental stimuli.
ncRNAs can be classiﬁed into three groups miRNAs, siRNAs,
and LncRNAs (Mercer et al., 2009; Ponting et al., 2009; Kaikko-
nen et al., 2011). The role these epigenetic modiﬁcations play in
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atherosclerosis and plaque rupture is poorly known in comparison
to the well-studied role they play in cancer.
Transgenerational epigenetic inheritance, which refers to the
transmission of epigenetic modiﬁcations from one generation to
the next, can affect the disease susceptibility of offspring (Kilpinen
and Dermitzakis, 2012; Skinner et al., 2012). The mechanism
behind these effects is not understood (Daxinger and Whitelaw,
2010). However, various epidemiological and population studies
have identiﬁed transgenerational effects, including modiﬁed car-
diovascular risk, due to changes in food supply (Lalande, 1996;
Kaati et al., 2002; Painter et al., 2008; Maloyan et al., 2013; Bygren
et al., 2014; Dominguez-Salas et al., 2014).
Epigenetics can be deﬁned as “The study of mitotically and/or
meiotically heritable changes in gene function that cannot be
explained by changes in DNA sequence” (Bird, 2002). Here we
deal with three well-studied epigenetic mechanisms (DNA methy-
lation, histone modiﬁcations, and ncRNAs), which have been the
focus of therapeutic intervention in CVD, through targeted drug
delivery or dietary supplementation.
DNA METHYLATION
Animal models have been used to connect DNA methyla-
tion/epigenetic modiﬁcations and CVD, further suggesting the
critical role of DNAmethylation in the development of atheroscle-
rosis and CVD (Baccarelli et al., 2010a; Bruneau, 2010; Shirodkar
and Marsden, 2011). Studies suggest that altered patterns in
methylation correlate with CVD (Castro et al., 2006; Kim et al.,
2007, 2010; Chen et al., 2010; McNeil et al., 2011; Soriano-Tárraga
et al., 2014; van Kampen et al., 2014; Yamada et al., 2014). Research
carried out on genomic DNA isolated from human atherosclerotic
lesions, has shown hypomethylation (Sharma et al., 2008). Hyper-
methylation of atherosclerotic lesions and the promoter region of
genes associated with atherosclerosis has also been identiﬁed in
various genes, e.g. superoxide dismutase, estrogen receptor alpha,
endothelial nitric oxide synthase, thus preventing their transcrip-
tion (Castro et al., 2006; Libby et al., 2010; Jia et al., 2013; Zaina
et al., 2014). Methylation of the estrogen receptor B-gene has also
been noted to contribute to atherosclerotic progression and is
largely associated with aging (Kim et al., 2007).
HISTONE POST-TRANSLATIONAL MODIFICATIONS
A variety of PTMs have been identiﬁed to date. Key PTMs
include acetylation, methylation and phosphorylation. These his-
tone modiﬁcations are carried out by various families of enzymes
which determine promoter accessibility (Arrowsmith et al., 2012).
PTMs are often due to the integration of environmental cues at a
cellular level and therefore have important roles in diseases related
to lifestyle, diet and early life exposure. A number of studies clearly
support a link between PTMs and atherosclerotic plaque vulner-
ability (Stein and Matter, 2011; Bleijerveld et al., 2013; Findeisen
et al., 2013; Bentzon et al., 2014; Eom and Kook, 2014; Pucci et al.,
2014). The repression of type 1 collagen has been identiﬁed as
a key step in atherogenesis, with a number of studies identi-
fying the modulators of its repression (e.g., Sin3B) and PTMs
which may result in its activation and subsequent plaque stabiliza-
tion (Kong et al., 2009; Weng et al., 2014). HDAC3 is also known
to be involved in plaque rupture; it was identiﬁed as the sole
histonedeacetylase (HDAC)upregulated in ruptured lesions. Inhi-
bition of HDAC3 shifts the phenotype of plaque macrophages to
anti-inﬂammatory and reduces lipid accumulation. Targeting this
HDAC may decrease the likelihood of plaque rupture (Hoeksema
et al., 2014)
NON-CODING RNA
The regulation of gene expression is inﬂuenced by ncRNAs, which
have the ability to alter gene expression in a variety of ways andplay
regulatory roles during development, the response to stress and
environmental stimuli. ncRNAs can be classiﬁed into three groups;
miRNAs, siRNAs, and LncRNAs (Mercer et al., 2009; Ponting et al.,
2009; Kaikkonen et al., 2011). miRNAs regulate genes from a dif-
ferent locus at a post transcriptional level, while siRNAs act to
silence the locus from which they are derived (Kaikkonen et al.,
2011). LncRNAs have multiple roles, their transcription alone can
often alter the expression of nearby genes, and they also carry out
essential regulatory roles (Wilusz et al., 2009). A number of stud-
ies have identiﬁed miRNAs and LncRNAs as key regulators in the
development of atherosclerosis (Motterle et al., 2012; Holdt et al.,
2013; Chen et al., 2014; Hu et al., 2014b; Liu et al., 2014a,b;Vausort
et al., 2014).
EPIGENETIC TARGETING AGENTS
The use of drugs which target the enzymes responsible for epi-
genetic modiﬁcations such as DNA methyl-transferases (DNMTs)
and HDACs have considerable therapeutic potential in CVD and
other inﬂammatory disorders. CVD therapeutic targets include
protein coding genes that have an already established relevance in
CVD (Poller et al., 2013). Drug therapies that work via epigenetic
mechanisms are largely unapproved by the FDA at present and
those that are mainly target blood related disorders (see Table 1
below). Dual therapies are also undergoing trails whereby histone
deacetylase inhibitor (HDACi) and DMNTs are combined. This
is likely to be used in addition to chemotherapy and interferon
treatment in cancer (Egger et al., 2004). In some cases, side effects
such as toxicity and non-speciﬁc gene modulation have limited
their use as cancer preventative agents (Zhang et al., 2013).
DNA METHYLTRANSFERASE INHIBITION
Findings have highlighted that epigenetic variation and modiﬁ-
cation are widely implicated in CVD. However, the mechanism
Table 1 | Current FDA approved epigenetic drugs.
Agent Epigenetic
mechanism
Application Year of approval
Vorinostat HDAC CTCL 2006
Romidepsin HDAC CTCL 2009
5-Azacytidine DNMT MDS 2004
Decitabine DNMT MDS 2006
Ruxolitinib JAK1/2 Myeloﬁbrosis 2011
CTCL, cutaneousT cell lymphoma; MDS, myelodysplastic syndrome.
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and result of these alterations remain widely unresolved. Con-
ﬂicting results as to the degree of DNA methylation isolated from
atherosclerotic lesions and from patient PBLs have been noted
(Castro et al., 2006; Sharma et al., 2008; Baccarelli et al., 2010a,b;
Chen et al., 2010). Hypermethylation of the promoter regions of
genes associatedwith atherogenesis has alsobeenobserved in genes
such as superoxide dismutase, further driving inﬂammation and
atherogenesis, implicating methylation as a potential therapeutic
target for the future (Buysschaert et al., 2008; Pons et al., 2009;
Libby et al., 2010; Lenfant, 2013).
HDACi
SULFORAPHANE AND NUTRITIONAL EPIGENETICS
Extensive epidemiological evidence and animal studies suggest
that cruciferous vegetables such as broccoli may help pre-
vent and/or delay various inﬂammatory disorders. Sulforaphane
[1-isothiocyanato-4-(methylsulﬁnyl)-butane] is thought to be
principally responsible for the health beneﬁts associated with
cruciferous vegetables due to its activity as a histone deacety-
lase inhibitor (Myzak et al., 2007; Elbarbry and Elrody, 2011).
Sulforaphane acts as an indirect antioxidant to induce the expres-
sion of several enzymes via epigenetic modiﬁcations of the Nrf2
pathway, which leads to the induction of its downstream anti-
oxidative stress pathway (Bai et al., 2013; Zhang et al., 2013).
Anti-oxidant response element (ARE) binds Nrf2 in the pro-
moter region, resulting in the induction of a series of anti-oxidant,
stress/detoxifying enzymes, and proteins, e.g., heme oxygenase-1
(HO-1), NAD(P)H dehydrogenase [quinone] 1 (NQO-1), uri-
dine 5’-diphospho-glucuronosyltransferas (UGT), glutathione S-
transferases (GST), ferretin, thioredoxin, thioredoxin reductase
1, and manganese superoxide dismutase (MnSOD) (Zhang et al.,
2013). Numerous epidemiological and animal studies support
sulforaphane’s role as an anti-oxidant and epigenetic modiﬁer,
suggesting that the risk of atherosclerosis and CVD could poten-
tially be reduced by its use (Zakkar et al., 2009; Evans, 2011;
Juurlink, 2012; Kim et al., 2012; Miao et al., 2012; Yoo et al.,
2013).
Sulforaphane has been shown to aid the suppression of inﬂam-
matory mediators such as VCAM-1 in endothelial cells, through
its activation of Nrf2 and alters the physiology of vascular and
inﬂammatory cells (Zakkar et al., 2009; Evans, 2011; Miao et al.,
2012). High shear stress results in the development of athero-
protected sites through activation of Nrf2. LSS does not, however,
activateNrf2 resulting inpro-inﬂammatory activation (Chen et al.,
2009; Zakkar et al., 2009). Pharmacological activation of Nrf2
using sulforaphane has been show to suppress p38 activation,
VCAM-1 expression and ROS production in cultured ECs and
in wild type mice. Nrf2–/– mice were unaffected by treatment
with sulforaphane, indicating that the anti-inﬂammatory effects
of Sulforaphane are Nrf2 dependent (Chen et al., 2009). This
implies that inﬂammation at athero-susceptible regions can be
reduced/prevented through sulforaphane mediated activation of
Nrf2. Dietary intervention in human subjects has demonstrated
that low concentrations of sulforaphane supplements can inhibit
HDAC activity (Myzak et al., 2007). To date sulforaphane is also
known to inhibit HDAC activity in human colorectal cancer cells
(Myzak et al., 2007).
CURCUMIN
Curcumin also offers great potential as a dietary atheroprotective
agent. Curcumin was shown to reduce the extent atherosclerotic
lesions and induce changes in the expression of genes involved
in cell adhesion, transendothelial migration in APOE–/– mice
fed with 0.2% curcumin over 4 months (Coban et al., 2012).
Oligomeric and monomeric ﬂavonoid consumption has been
demonstrated to modulate the expression of genes associated with
CVD (Milenkovic et al., 2014). These studies highlight a new angle
for the treatment and prevention of CVD through the use of
dietary supplements. Curcuminwhenpackagedwith sulforaphane
has been suggested as a chemotherapeutic option for the treat-
ment of pancreatic cancer (Jayaraman et al., 2012; Sutaria et al.,
2012).
PROTOCATECHUIC ALDEHYDE
Protocatechuic aldehyde (PA), an established HDACi, is a com-
pound isolated from the aqueous extract of the root of the Salvia
miltiorrhiza herb. It has been widely used in traditional Chinese
medicine to treat various vascular diseases. There is evidence to
suggest that PA can inhibit migration and proliferation of vascular
smooth muscle cells (Moon et al., 2012). PA has been shown to
affect the expression of adhesion molecules in human umbilical
vein endothelial cells (HUVECs) stimulated with TNF-α, suggest-
ing that PA inhibits TNF-α stimulated VCAM-1 and intercellular
adhesion molecule-1 (ICAM-1) expression in these cells through a
mechanism that involves NF-κB and AP-1 (Zhou et al., 2005). The
role of PA in myocardial ischemia and reperfusion injury has been
investigated to determine its anti-inﬂammatory effect in vivo and
its use as a potential therapeutic agent. The use of a rat model sug-
gested that PA could protect the heart from myocardial ischemia
and reperfusion injury by reducing myocardial infarct size and
the activities of creatine kinase-MB and cardiac troponin (Wei
et al., 2013). As with sulforaphane, the above studies of PA suggest
the use of dietary supplements which act as HDAC inhibitors to
help prevent the development and progression of atherosclerotic
plaque.
miRNA BIOMARKERS AND INTERVENTIONS
Studies are currently investigating a potential link betweenmiRNA
expression proﬁles, plaque development, and rupture. The use
of miRNAs in therapy includes organ targeted RNAi using viral
vectors or synthetic RNA, and therapeutic strategies on the basis
of modulation of miRNA function (Poller et al., 2013). However,
challenges remain with issues such as speciﬁcity, as the 3′ UTR
of a single mRNA can be targeted by multiple miRNAs. miR-
NAs also exert many different actions dependent on cell type;
hence miRNA modulation therapies require precise cellular tar-
geting and suitable delivery methods. For example miR-144-3p
has been shown to accelerate plaque formation through the post
transcriptional regulation of ABCA1. ABCA1 has a critical role in
cellular cholesterol efﬂux and the formation of HDL. Inhibition
of ABCA1 through miR-144-3p has been shown in THP-1 cells
and inAPOE–/– mice to increase inﬂammatory cytokine secretion
and accelerate plaque formation (Hu et al., 2014a). This highlights
how essential it is for appropriate miRNA targeting in atheroscle-
rosis as one miRNA can inﬂuence multiple pathways. miRNA
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expression proﬁles are also likely to differ between atheroscle-
rotic plaques and healthy arteries, and may provide useful markers
and targets in atherosclerosis (Wierda et al., 2010; Cipollone et al.,
2011; Raitoharju et al., 2011; Hao et al., 2014; Menghini et al.,
2014).
Many of the genes down regulated included those involved in
the regulation of signal transduction, transcription, and vesicular
transport. Those which were up regulated are thought to be
involved in the key processes of atherosclerosis (Wierda et al., 2010;
Raitoharju et al., 2011).
Cipollone et al. (2011) investigated whether a unique miRNA
signature was associated with plaque instability in humans. They
identiﬁed ﬁve miRNAs, miR-100, miR-127, miR-145, miR-133a,
and miR-133b which had altered expression levels. Expression
of these miRNAs was greater in symptomatic plaques from
patients with ischemic stroke, suggesting a role for miRNAs in
plaque instability and rupture, but also as predictive biomark-
ers. Further ﬁndings implicate miRNAs such as miR-24 and
miR-21 in the regulation of matrix metalloproteinase (MMPs),
known to play a part in ﬁbrous cap thinning and in turn plaque
rupture (Di Gregoli et al., 2014; Fan et al., 2014). Endothelial
miRNAs are likely to be selectively regulated by arterial ﬂow
conditions, particularly the combination of pro-atherogenic LSS
and oxidized low-density lipoprotein (oxLDL) which induce
the upregulation of miR-92a, suggesting the use of a miR-
92a antagomir as a potential therapeutic option (Loyer et al.,
2014).
The potential future use of miRNAs in diagnosis and as treat-
ment options remains promising, as a recent article highlights the
effect of an RNAi drug ALN-PCS on the synthesis of proprotein
convertase subtilisin/kexin type 9 (PCSK9), in one of the ﬁrst
successful applications of RNAi therapeutics in a clinical setting
(Abifadel et al., 2003; Zhao et al., 2006; Fitzgerald et al., 2014).
Treatment resulted in a mean 70% reduction in circulating PCSK9
plasma protein and a mean 40% reduction in LDL cholesterol
from baseline relative to placebo (Fitzgerald et al., 2014). Anti
miR-133 therapy has also been shown to reduce the progression
of atherosclerosis and improve HDL function in Ldlr –/– mice
(Rotllan et al., 2013).
Circulating miRNAs have also attracted considerable attention
as potential biomarkers, as they can be detected in blood and
potentially used for the risk stratiﬁcation of patients (Deiuliis
et al., 2014). Fichtlscherer et al identiﬁed four miRNAs which were
reduced in patients with CAD compared to healthy controls, miR-
126, miR-17, miR-92a, and miR-155. Muscle enriched miRNAs
were also found to be more highly expressed in patients with
CAD compared to volunteers (Fichtlscherer et al., 2010; Stellos
and Dimmeler, 2014). miRNAs are also involved in the regulation
of macrophage phenotype alterations from inﬂammatory to anti-
inﬂammatory, and they can be altered by shear stress (Boettger
et al., 2009; Alexy et al., 2014; De Paoli et al., 2014). These stud-
ies clearly identify a correlation between miRNA expression and
plaque instability. A number of considerations must also be taken
into account such as whether the patients were receiving statins or
other cholesterol modifying drugs, as this could alter/contribute
to the miRNA expression observed by acting as epigenetic
modiﬁers.
CONCLUSION
Recent trends have seen advances in the progression of epige-
netic drugs from bench to bedside, further supporting their
importance as key drugs of the future. However many of the
therapies targeting atherosclerotic disease remain unavailable for
use in a clinical setting. Issues such as delivery of miRNAs to
localized areas remain. However, we are now beginning to see
the use of nanoparticles to deliver epigenetic inhibitors such as
sulforaphane and ALN-PCS. The speciﬁcity of epigenetic ther-
apies is also a consideration, as non-speciﬁc effects may result
in gene activation/inhibition that may further hinder treatment.
Unlike cancer, epigenetic therapy for atherosclerotic disease is still
in its infancy, yet it represents a topic of great global concern as it
is the main cause of death in the western world. Future directions
and preventative measures may include the biomarker proﬁling of
patients with high and low risk plaques through the use of cir-
culating miRNAs, leading to considerable economic and health
beneﬁts.
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